Vanda Pharmaceuticals (VNDA) Announces Exclusive License Agreement with Megapharm for Commercialization of Fanapt in Israel
Up)
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) today announced its exclusive license agreement with Megapharm Ltd., one of Israel's leading private biotech, pharmaceutical and medical nutrition marketing companies, for the commercialization of Fanapt™ in Israel.
Under the terms of the agreement, Megapharm will seek regulatory approval for Fanapt™ in Israel. Vanda will supply Megapharm with Fanapt™ drug product for packaging and sale and Megapharm's CNS specialty sales force will promote Fanapt™ to psychiatrists in Israel. The application for regulatory approval of Fanapt™ in Israel was filed in May 2011.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Under the terms of the agreement, Megapharm will seek regulatory approval for Fanapt™ in Israel. Vanda will supply Megapharm with Fanapt™ drug product for packaging and sale and Megapharm's CNS specialty sales force will promote Fanapt™ to psychiatrists in Israel. The application for regulatory approval of Fanapt™ in Israel was filed in May 2011.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Syngenta (SYT) settles atrazine litigation; will pay $105M in deal
- BlackRock (BLK) Substantially Boosts Stake in Chesapeake (CHK) -CNBC's Kelly
- Pfizer (PFE) Axitinib Gets Positive Opinion from CHMP EMA
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
